Sign Up
OverviewAPI
Novo Nordisk, a Denmark-based drugmaker, seeks 'bolt-on' deals for early- to mid-stages of development, focusing on diabetes, obesity, cardiovascular disease, rare blood disorders, haemophilia, and sickle cell. The company plans to invest $6 billion to expand its production in Denmark, aiming to meet the global demand for weight-loss drugs. Novo Nordisk's market capitalization is over $439 billion, but its foundation-controlled structure has constrained growth, particularly in meeting the demand for Ozempic and Wegovy. The company plans to invest $3.6 billion to expand global production but expects demand to continue outpacing supply in the short to midterm.

Ask a question